Pharmasset cancels hepatitis drug development - Forbes.com

"Pharmasset Inc. said Monday it is ending development of its most advanced drug candidate, clevudine, over concerns of severe muscle weakness in hepatitis B patients.

Pharmasset said it made the decision to end the late-stage Quash studies voluntarily, following discussions with an independent monitoring board and the Food and Drug Administration. The company is maintaining its focus on a separate hepatitis C program with its partner Roche ( RHHBY.PK - news - people )."